A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


June 3, 2011

Unrealistic Expectations Might Reduce PrEP Acceptability

A new study suggests there might be a very high bar for acceptance of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM), transgender females and female sex workers. The study, published in the May 5 issue of the International Journal of STD & AIDS, found that PrEP would need to be cheap, highly effective and used only intermittently before these groups would want to use it.

Ever since the news broke in late 2010 that a Truvada (tenofovir plus emtricitabine) PrEP regimen could reduce new HIV infections by 44 percent or more, experts and community members have been questioning how to safely roll out this new prevention intervention and whether people would even want to use it. Scientists and public health experts had assumed that PrEP—whereby HIV-negative people take antiretroviral (ARV) medication to prevent becoming infected—would likely work, but they remained uncertain how to use it if studies confirmed its efficacy.

Subsequently, researchers with the University of California in Los Angeles partnered with researchers at the Cayetano Heredia University School of Public Health in Lima, Peru, to begin answering this key question.

“Just a few months ago, we learned that PrEP can prevent HIV infection, but it has not been deployed on a large scale yet and is a topic of debate in the HIV-prevention research community,” said Jerome Galea, Latin America regional director for the UCLA Program in Global Health and one of the study’s co-investigators.

Galea and his colleagues turned to the same populations that were included in the original iPrEx PrEP study—mostly Peruvian MSM and female transgenders—plus female sex workers and presented them with a number of scenarios to determine what factors would influence their likelihood to use PrEP.

Specifically, Galea’s team assessed PrEP acceptability using two methods—focus groups and conjoint analysis—that product manufactures frequently use to figure out how to market a new consumer product. With conjoint analysis, people are given a range of various related options—such as varying price—to see what factors most influence their choices.

“This is the first study of its kind to apply this specific market research technique to understand what the ‘consumers’ of PrEP valued most about this method of prevention,” Galea said.

For the study, the researchers divided 45 participants into seven groups of four to eight individuals, with each participating in both the focus groups and the conjoint analysis exercise.

In the focus groups, researchers looked for patterns of knowledge about PrEP, and what participants believed would most influence their decisions—and that of their peers—to use PrEP. In the coinjoint analysis, participants were asked to choose between a range of options that included out-of-pocket costs, efficacy, side effects and duration of use and dosing.
The conjoint analysis revealed that a low out-of-pocket cost was the most important factor to the participants.

“While we expected cost to be an important factor, we were surprised that it was more important than the ability of the product to actually prevent HIV infection,” Galea said.
Taken together, people said that they would be most likely to use PrEP if it was low cost, had 95 percent efficacy, no side effects, and could be taken just before having sex. Given that PrEP must be taken daily and only approached 95 percent efficacy in people whose blood levels confirmed that they took it regularly—and given that another recent PrEP trial in heterosexual couples ended for lack of ability to show efficacy—these desires appear unrealistic.

Because the study was small and included only a narrow subsection of those to whom PrEP would likely be offered, Galea and his team are recommending that further research is needed.

“We cannot generalize our findings to all persons at risk for HIV, in Peru or elsewhere,” he said. “But we do propose it as a model for future exploration of the topic, now that oral PrEP has been shown to work but has not yet been scaled up for widespread use.”

Search: PrEP, iPrEx, Truvada, tenofovir, emtricitabine, Jerome Galea, UCLA, Lima, Peru, sex workers, MSM, gay, transgender

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.